Casopitant Mesylate

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameCasopitant Mesylate
Drug Alias NameCasopitantum卡索匹坦CasopitantZunrisaRezonic +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 1 receptor antagonists
TargetsNeurokinin 1 receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingSolid tumoursDepressive Disorder, Major +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[47] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsChemotherapy-induced nausea and vomitingSolid tumoursDepressive Disorder, Major +[13] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG